Emerging promise of epigenetics and DNA methylation for the diagnosis and management of womens cancers

Epigenomics

Volumn 2, Issue 1, 2010, Pages 9-38

  Jones, Allison ^a   Lechner, Matthias ^a   Fourkala, Evangelia Ourania ^a   Kristeleit, Rebecca ^a   Widschwendter, Martin ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

breast cancer; cervical cancer; DNA methylation; DNA methylation marker; DNMT inhibitor; endometrial cancer; epigenetics; gynecological cancer; HDAC inhibitor; ovarian cancer; therapeutic target

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; BELINOSTAT; BISULFITE; CAPECITABINE; CARBOPLATIN; DEPSIPEPTIDE; DNA METHYLTRANSFERASE 1; ESTROGEN RECEPTOR; EXEMESTANE; GEMCITABINE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; N PHTHALOYLTRYPTOPHAN; PACLITAXEL; PANOBINOSTAT; ROMIDEPSIN; TAMOXIFEN; TRASTUZUMAB; VORINOSTAT;

ADVANCED CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARCINOGENESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CPG ISLAND; DNA METHYLATION; DNA REPLICATION; EARLY DIAGNOSIS; ENDOMETRIUM CANCER; EPIGENETICS; GENETIC ASSOCIATION; HUMAN; IMMUNOPRECIPITATION; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; UPREGULATION; UTERINE CERVIX CANCER; WOMEN'S HEALTH;

BREAST NEOPLASMS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENITAL NEOPLASMS, FEMALE; GONADAL STEROID HORMONES; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNOPRECIPITATION; MODELS, BIOLOGICAL; MULLERIAN DUCTS; RESTRICTION MAPPING; SULFITES; TUMOR MARKERS, BIOLOGICAL;

EID: 77954093340     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.09.47     Document Type: Review

References (252)

1. Feinberg AP, Tycko B: The history of cancer epigenetics. Nat. Rev. Cancer 4(2), 143-153 (2004).
2. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3(6), 415-428 (2002).
3. Ligtenberg MJ, Kuiper R P, Chan TL et al.: Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3́ exons of TACSTD1. Nat. Genet. 41(1), 112-117 (2009).
4. Weinberg MS, Villeneuve LM, Ehsani A et al.: The antisense strand of small interfering RNAs directs histone methylation and transcriptional gene silencing in human cells. RNA 12(2), 256-262 (2006).
5. Ting AH, Schuebel KE, Herman JG, Baylin SB: Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation. Nat. Genet. 37(8), 906-910 (2005).
6. Camblong J, Iglesias N, Fickentscher C, Dieppois G, Stutz F: Antisense RNA stabilization induces transcriptional gene silencing via histone deacetylation in S. cerevisiae. Cell 131(4), 706-717 (2007).
7. Schuettengruber B, Chourrout D, Vervoort M, Leblanc B, Cavalli G: Genome regulation by polycomb and trithorax proteins. Cell 128(4), 735-745 (2007).
8. Fitzpatrick GV, Pugacheva EM, Shin JY et al.: Allele-specifc binding of CTCF to the multipartite imprinting control region KvDMR1. Mol. Cell. Biol. 27(7), 2636-2647 (2007).
9. Terranova R, Yokobayashi S, Stadler MB et al.: Polycomb group proteins Ezh2 and Rnf2 direct genomic contraction and imprinted repression in early mouse embryos. Dev. Cell 15(5), 668-679 (2008).
10. Matzke MA, Birchler JA: RNAi-mediated pathways in the nucleus. Nat. Rev. Genet. 6(1), 24-35 (2005).
11. Feinberg A P, Tycko B: The history of cancer epigenetics. Nat. Rev. Cancer 4(2), 143-153 (2004).
12. Sharma S, Kelly TK, Jones PA: Epigenetics in cancer. Carcinogenesis 31(1), 27-36 (2009).
13. Bird A: DNA methylation patterns and epigenetic memory. Genes Dev. 16(1), 6-21 (2002).
14. Bird AP, Wolffe AP: Methylation-induced repression-belts, braces, and chromatin. Cell 99(5), 451-454 (1999).
15. Hendrich B, Bird A: Mammalian methyltransferases and methyl-CpG-binding domains: proteins involved in DNA methylation. Curr. Top. Microbiol. Immunol. 249, 55-74 (2000).
16. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3(6), 415-428 (2002).
17. Bird AP: CpG-rich islands and the function of DNA methylation. Nature 321(6067), 209-213 (1986).
18. Jones PA, Takai D: The role of DNA methylation in mammalian epigenetics. Science 293(5532), 1068-1070 (2001).
19. Reik W: Stability and fexibility of epigenetic gene regulation in mammalian development. Nature 447(7143), 425-432 (2007).
20. Fraga MF, Agrelo R, Esteller M: Cross-talk between aging and cancer: the epigenetic language. Ann. NY Acad. Sci. 1100, 60-74 (2007).
21. Jones PA, Baylin SB: The epigenomics of cancer. Cell 128(4), 683-692 (2007).
22. Bird A: Perceptions of epigenetics. Nature 447(7143), 396-398 (2007).
23. Widschwendter M, Jones PA: The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer. Commentaryre
24. J. Kwong et al., promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res. 8, 131-137, 2002
25. H-Z. Zou et al., detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin. Cancer Res. 8: 188-191, 2002.
26. Clin. Cancer Res. 8(1), 17-21 (2002)
27. Barton CA, Hacker NF, Clark SJ, O'Brien PM: DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol. Oncol. 109(1), 129-139 (2008).
28. Zhou XC, Dowdy SC, Podratz KC, Jiang SW: Epigenetic considerations for endometrial cancer prevention, diagnosis and treatment. Gynecol. Oncol. 107(1), 143-153 (2007).
29. Duenas-Gonzalez A, Lizano M, Candelaria M, Cetina L, Arce C, Cervera E: Epigenetics of cervical cancer. An overview and therapeutic perspectives. Mol. Cancer 4, 38 (2005).
30. Feinberg AP, Vogelstein B: Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301(5895), 89-92 (1983).
31. Friedenreich CM: Review of anthropometric factors and breast cancer risk. Eur. J. Cancer Prev. 10(1), 15-32 (2001).
32. Bjornsson HT, Fallin MD, Feinberg AP: An integrated epigenetic and genetic approach to common human disease. Trends Genet. 20(8), 350-358 (2004).
33. Knudson A: Alfred Knudson and his two-hit hypothesis. (interview by Ezzie Hutchinson). Lancet Oncol. 2(10), 642-645 (2001).
34. Gosden RG, Feinberg AP: Genetics and epigenetics-nature's pen-and-pencil set. N. Engl. J. Med 356(7), 731-733 (2007).
35. Widschwendter M, Fiegl H, Egle D et al.: Epigenetic stem cell signature in cancer. Nat. Genet. 39(2), 157-158 (2007).
36. Tang WY, Ho SM: Epigenetic reprogramming and imprinting in origins of disease. Rev. Endocr. Metab. Disord. 8(2), 173-182 (2007).
37. Sato K, Fukata H, Kogo Y, Ohgane J, Shiota K, Mori C: Neonatal exposure to diethylstilbestrol alters the expression of DNA methyltransferases and methylation of genomic DNA in the epididymis of mice. Endocr. J. 53(3), 331-337 (2006).
38. Widschwendter M, Siegmund KD, Muller HM et al.: Association of breast cancer DNA methylation profles with hormone receptor status and response to tamoxifen. Cancer Res. 64(11), 3807-3813 (2004).
39. Widschwendter M, Apostolidou S, Raum E et al.: Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS ONE 3(7), E2656 (2008).
40. Strobl JS, Thompson EB: Methylation of either cytosine in the recognition sequence CGCG inhibits ThaI cleavage of DNA. Nucleic Acids Res. 12(21), 8073-8083 (1984).
41. Sneider TW: The 5́-cytosine in CCGG1 is methylated in two eukaryotic DNAs and Msp I is sensitive to methylation at this site. Nucleic Acids Res. 8(17), 3829-3840 (1980).
42. McClelland M: The effect of sequence specifc DNA methylation on restriction endonuclease cleavage. Nucleic Acids Res. 9(22), 5859-5866 (1981).
43. Esteller M: Cancer epigenomics: DNA methylomes and histone-modifcation maps. Nat. Rev. Genet. 8(4), 286-298 (2007).
44. Ammerpohl O, Martin-Subero JI, Richter J, Vater I, Siebert R: Hunting for the 5th base: techniques for analyzing DNA methylation. Biochim. Biophys. Acta 1790(9), 847-862 (2009).
45. Bird AP, Southern EM: Use of restriction enzymes to study eukaryotic DNA methylation: I. The methylation pattern in ribosomal DNA from Xenopus laevis. J. Mol. Biol. 118(1), 27-47 (1978).
46. Bedford MT, van Helden PD: A method to analyze allele-specifc methylation. Biotechniques 9(6), 744-748 (1990).
47. Welsh J, McClelland M: Fingerprinting genomes using PCR with arbitrary primers. Nucleic Acids Res. 18(24), 7213-7218 (1990).
48. Gonzalgo ML, Liang G, Spruck CH 3rd, Zingg JM, Rideout WM 3rd, Jones PA: Identifcation and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR. Cancer Res. 57(4), 594-599 (1997).
49. Costa FF, Paixao VA, Cavalher FP et al.: Satr-1 hypomethylation is a common and early event in breast cancer. Cancer Genet. Cytogenet. 165(2), 135-143 (2006).
50. Hatada I, Hayashizaki Y, Hirotsune S, Komatsubara H, Mukai T: A genomic scanning method for higher organisms using restriction sites as landmarks. Proc. Natl Acad. Sci. USA 88(21), 9523-9527 (1991).
51. Wang SS, Smiraglia DJ, Wu YZ et al.: Identifcation of novel methylation markers in cervical cancer using restriction landmark genomic scanning. Cancer Res. 68(7), 2489-2497 (2008).
52. Huang TH, Perry MR, Laux DE: Methylation profling of CpG islands in human breast cancer cells. Hum. Mol. Genet. 8(3), 459-470 (1999).
53. Wolber PK, Collins PJ, Lucas AB, De Witte A, Shannon KW: The agilent in situ-synthesized microarray platform. Methods Enzymol. 410, 28-57 (2006).
54. Ahluwalia A, Yan P, Hurteau JA et al.: DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol. Oncol. 82(2), 261-268 (2001).
55. Yan PS, Chen CM, Shi H, Rahmatpanah F, Wei SH, Huang TH: Applications of CpG island microarrays for high-throughput ana lysis of DNA methylation. J. Nutr. 132(8 Suppl.), S2430-S2434 (2002).
56. Zighelboim I, Goodfellow PJ, Schmidt AP et al.: Differential methylation hybridization array of endometrial cancers reveals two novel cancer-specifc methylation markers. Clin. Cancer Res. 13(10), 2882-2889 (2007).
57. Frommer M, Mcdonald LE, Millar DS et al.: A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl Acad. Sci. USA 89(5), 1827-1831 (1992).
58. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specifc PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93(18), 9821-9826 (1996).
59. Eads CA, Danenberg KD, Kawakami K et al.: Methylight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 28(8), E32 (2000).
60. Kristensen LS, Mikeska T, Krypuy M, Dobrovic A: Sensitive melting ana lysis after real time-methylation specifc PCR (SMART-MSP): high-throughput and probe-free quantitative DNA methylation detection. Nucleic Acids Res. 36(7), E42 (2008).
61. Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB, Herman JG: In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc. Natl Acad. Sci. USA 96(22), 12754-12759 (1999).
62. Xiong Z, Laird PW: COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 25(12), 2532-2534 (1997).
63. Rauch T, Pfeifer GP: Methylated-CpG island recovery assay: a new technique for the rapid detection of methylated-CpG islands in cancer. Lab. Invest. 85(9), 1172-1180 (2005).
64. Rauch T, Li H, Wu X, Pfeifer GP: Mira-assisted microarray ana lysis, a new technology for the determination of DNA methylation patterns, identifes frequent methylation of homeodomain-containing genes in lung cancer cells. Cancer Res. 66(16), 7939-7947 (2006).
65. Tommasi S, Karm DL, Wu X, Yen Y, Pfeifer GP: Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. Breast Cancer Res. 11(1), R14 (2009).
66. Weber M, Davies JJ, Wittig D et al.: Chromosome-wide and promoter-specifc analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat. Genet. 37(8), 853-862 (2005).
67. Gama-Sosa MA, Slagel VA, Trewyn RW et al.: The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. 11(19), 6883-6894 (1983).
68. Weisenberger DJ, Trinh BN, Campan M et al.: DNA methylation ana lysis by digital bisulfte genomic sequencing and digital methylight. Nucleic Acids Res. 36(14), 4689-4698 (2008).
69. Fan JB, Gunderson KL, Bibikova M et al.: Illumina universal bead arrays. Methods Enzymol. 410, 57-73 (2006).
70. Bibikova M, Lin Z, Zhou L et al.: High-throughput DNA methylation profling using universal bead arrays. Genome Res. 16(3), 383-393 (2006).
71. Gonzalgo ML, Jones PA: Rapid quantitation of methylation differences at specifc sites using methylation-sensitive single nucleotide primer extension (MS-SNUPE). Nucleic Acids Res. 25(12), 2529-2531 (1997).
72. Flanagan JM, Munoz-Alegre M, Henderson S et al.: Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. Hum. Mol. Genet. 18(7), 1332-1342 (2009).
73. Irizarry RA, Ladd-Acosta C, Wen B et al.: The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specifc CpG island shores. Nat. Genet. 41(2), 178-186 (2009).
74. Suzuki MM, Bird A: DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet. 9(6), 465-476 (2008).
75. Korshunova Y, Maloney RK, Lakey N et al.: Massively parallel bisulphite pyrosequencing reveals the molecular complexity of breast cancer-associated cytosine-methylation patterns obtained from tissue and serum DNA. Genome Res. 18(1), 19-29 (2008).
76. Clarke J, Wu HC, Jayasinghe L, Patel A, Reid S, Bayley H: Continuous base identifcation for single-molecule nanopore DNA sequencing. Nat. Nanotechnol. 4(4), 265-270 (2009).
77. Dubeau L: The cell of origin of ovarian epithelial tumours. Lancet Oncol. 9(12), 1191-1197 (2008).
78. Ibanez De Caceres I, Battagli C, Esteller M et al.: Tumor cell-specifc BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fuid from ovarian cancer patients. Cancer Res. 64(18), 6476-6481 (2004).
79. Risinger JI, Maxwell GL, Berchuck A, Barrett JC: Promoter hypermethylation as an epigenetic component in type I and type II endometrial cancers. Ann. NY Acad. Sci. 983, 208-212 (2003).
80. Xiong Y, Dowdy SC, Xue A et al.: Opposite alterations of DNA methyltransferase gene expression in endometrioid and serous endometrial cancers. Gynecol. Oncol. 96(3), 601-609 (2005).
81. Fiegl H, Gattringer C, Widschwendter A et al.: Methylated DNA collected by tampons-a new tool to detect endometrial cancer. Cancer Epidemiol. Biomarkers Prev. 13(5), 882-888 (2004).
82. Wisman GB, Nijhuis ER, Hoque MO et al.: Assessment of gene promoter hypermethylation for detection of cervical neoplasia. Int. J. Cancer 119(8), 1908-1914 (2006).
83. Yang X, Yan L, Davidson NE: DNA methylation in breast cancer. Endocr. Relat. Cancer 8(2), 115-127 (2001).
84. Wei SH, Balch C, Paik HH et al.: Prognostic DNA methylation biomarkers in ovarian cancer. Clin. Cancer Res. 12(9), 2788-2794 (2006).
85. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R: The acquisition of HMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin. Cancer Res. 10(13), 4420-4426 (2004).
86. Suehiro Y, Okada T, Okada T et al.: Aneuploidy predicts outcome in patients with endometrial carcinoma and is related to lack of CDH13 hypermethylation. Clin. Cancer Res. 14(11), 3354-3361 (2008).
87. Powell MA, Mutch DG, Rader JS, Herzog TJ, Huang TH, Goodfellow PJ: Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker. Cancer 94(11), 2941-2952 (2002).
88. Muller HM, Fiegl H, Widschwendter A, Widschwendter M: Prognostic DNA methylation marker in serum of cancer patients. Ann. NY Acad. Sci. 1022, 44-49 (2004). (Pubitemid 38951580)
89. Widschwendter A, Ivarsson L, Blassnig A et al.: CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int. J. Cancer 109(2), 163-166 (2004).
90. Teodoridis JM, Hall J, Marsh S et al.: CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res. 65(19), 8961-8967 (2005).
91. Feng Q, Deftereos G, Hawes SE et al.: DNA hypermethylation, Her-2/neu overexpression and p53 mutations in ovarian carcinoma. Gynecol. Oncol. 111(2), 320-329 (2008).
92. Strathdee G, Vass JK, Oien KA, Siddiqui N, Curto-Garcia J, Brown R: Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol. Oncol. 97(3), 898-903 (2005).
93. Fiegl H, Millinger S, Mueller-Holzner E et al.: Circulating tumor-specifc DNA: a marker for monitoring effcacy of adjuvant therapy in cancer patients. Cancer Res. 65(4), 1141-1145 (2005).
94. Fiegl H, Jones A, Hauser-Kronberger C et al.: Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer. Clin. Cancer Res. 14(11), 3494-3502 (2008).
95. Martens JW, Nimmrich I, Koenig T et al.: Association of DNA methylation of phosphoserine aminotransferase with response to endocrine therapy in patients with recurrent breast cancer. Cancer Res. 65(10), 4101-4117 (2005).
96. Bernstein BE, Meissner A, Lander ES: The mammalian epigenome. Cell 128(4), 669-681 (2007).
97. Schickel R, Boyerinas B, Park SM, Peter ME: MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 27(45), 5959-5974 (2008).
98. Kuendgen A, Lubbert M: Current status of epigenetic treatment in myelodysplastic syndromes. Ann. Hematol. 87(8), 601-611 (2008).
99. Olsen EA, Kim YH, Kuzel TM et al.: Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25(21), 3109-3115 (2007).
100. Saito Y, Suzuki H, Tsugawa H et al.: Chromatin remodeling at Alu repeats by epigenetic treatment activates silenced microRNA-512-5p with downregulation of Mcl-1 in human gastric cancer cells. Oncogene 28(30), 2738-2744 (2009).
101. Datta J, Ghoshal K, Denny WA et al.: A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. Cancer Res. 69(10), 4277-4285 (2009).
102. Mund C, Brueckner B, Lyko F: Reactivation of epigenetically silenced genes by DNA methyltransferase inhibitors: basic concepts and clinical applications. Epigenetics 1(1), 7-13 (2006).
103. Steele NL, Plumb JA, Vidal L et al.: A Phase I pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin. Cancer Res. 14(3), 804-810 (2008).
104. Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F: Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res. 66(5), 2794-2800 (2006).
105. Stresemann C, Lyko F: Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Cancer 123(1), 8-13 (2008).
106. Saito Y, Jones PA: Epigenetic activation of tumor suppressor microRNAs in human cancer cells. Cell Cycle 5(19), 2220-2222 (2006).
107. Widschwendter M, Jiang G, Woods C et al.: DNA hypomethylation and ovarian cancer biology. Cancer Res. 64(13), 4472-4480 (2004).
108. Gaudet F, Hodgson JG, Eden A et al.: Induction of tumors in mice by genomic hypomethylation. Science 300(5618), 489-492 (2003).
109. Chekhun VF, Kulik GI, Yurchenko OV et al.: Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells. Cancer Lett. 231(1), 87-93 (2006).
110. Gius D, Cui H, Bradbury CM et al.: Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 6(4), 361-371 (2004).
111. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S: Human papillomavirus and cervical cancer. Lancet 370(9590), 890-907 (2007).
112. Issa JP, Kantarjian HM: Targeting DNA methylation. Clin. Cancer Res. 15(12), 3938-3946 (2009).
113. Schermelleh L, Spada F, Easwaran HP et al.: Trapped in action: direct visualization of DNA methyltransferase activity in living cells. Nat. Methods 2(10), 751-756 (2005).
114. Ghoshal K, Datta J, Majumder S et al.: 5-aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the ken box, bromo-adjacent homology domain, and nuclear localization signal. Mol. Cell. Biol. 25(11), 4727-4741 (2005).
115. Jones PA, Taylor SM: Cellular differentiation, cytidine analogs and DNA methylation. Cell 20(1), 85-93 (1980).
116. Yoo CB, Jones PA: Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug Discov. 5(1), 37-50 (2006).
117. Yoo CB, Jeong S, Egger G et al.: Delivery of 5-aza-2́-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res. 67(13), 6400-6408 (2007).
118. Beumer JH, Eiseman JL, Parise RA et al.: Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fuoro-2́-deoxycytidine in mice. Clin. Cancer Res. 12(24), 7483-7491 (2006).
119. Beumer JH, Parise RA, Newman EM et al.: Concentrations of the DNA methyltransferase inhibitor 5-fuoro-2́-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Cancer Chemother. Pharmacol. 62(2), 363-368 (2008).
120. Hamajima N, Hirose K, Tajima K et al.: Alcohol, tobacco and breast cancer-collaborative reana lysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br. J. Cancer 87(11), 1234-1245 (2002).
121. Appleton K, Mackay HJ, Judson I et al.: Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J. Clin. Oncol. 25(29), 4603-4609 (2007).
122. Piekarz RL, Bates SE: Epigenetic modifers: basic understanding and clinical development. Clin. Cancer Res. 15(12), 3918-3926 (2009).
123. Plummer R, Vidal L, Griffn M et al.: Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors. Clin. Cancer Res. 15(9), 3177-3183 (2009).
124. Klisovic RB, Stock W, Cataland S et al.: A Phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia. Clin. Cancer Res. 14(8), 2444-2449 (2008).
125. Schirrmacher E, Beck C, Brueckner B et al.: Synthesis and in vitro evaluation of biotinylated RG108: a high affnity compound for studying binding interactions with human DNA methyltransferases. Bioconjug. Chem. 17(2), 261-266 (2006).
126. Glasspool RM, Gore M, Rustin G et al.: Randomized Phase II study of decitabine in combination with carboplatin compared with carboplatin alone in patients with recurrent advanced ovarian cancer. J. Clin. Oncol. 27(Suppl. 15) (2009) (Abstract 5562).
127. Pohlmann P, Dileone LP, Cancella AI et al.: Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am. J. Clin. Oncol. 25(5), 496-501 (2002).
128. Braiteh F, Soriano AO, Garcia-Manero G et al.: Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers. Clin. Cancer Res. 14(19), 6296-6301 (2008).
129. Michael DG, Adamson P, Alexopoulos T et al.: Observation of muon neutrino disappearance with the minos detectors in the numi neutrino beam. Phys. Rev. Lett. 97(19), 191801 (2006).
130. De Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J. 370(Pt 3), 737-749 (2003).
131. Kouzarides T: Chromatin modifcations and their function. Cell 128(4), 693-705 (2007).
132. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W: Acetylation is indispensable for p53 activation. Cell 133(4), 612-626 (2008).
133. Bolden JE, Peart MJ, Johnstone RW: Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5(9), 769-784 (2006).
134. Lindemann RK, Gabrielli B, Johnstone RW: Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 3(6), 779-788 (2004).
135. Scroggins BT, Robzyk K, Wang D et al.: An acetylation site in the middle domain of Hsp90 regulates chaperone function. Mol. Cell 25(1), 151-159 (2007).
136. Morales V, Richard-Foy H: Role of histone N-terminal tails and their acetylation in nucleosome dynamics. Mol. Cell. Biol. 20(19), 7230-7237 (2000).
137. Sengupta PP, Northfelt DW, Gentile F, Zamorano JL, Khandheria BK: Trastuzumab-induced cardiotoxicity: heart failure at the crossroads. Mayo Clin. Proc. 83(2), 197-203 (2008).
138. Johnstone RW: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1(4), 287-299 (2002).
139. Richon VM, Sandhoff TW, Rifkind RA, Marks PA: Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl Acad. Sci. USA 97(18), 10014-10019 (2000).
140. Atadja P, Gao L, Kwon P et al.: Selective growth inhibition of tumor cells by a novel histone deacetylase inhibitor, NVP-LAQ824. Cancer Res. 64(2), 689-695 (2004).
141. Vigushin DM, Coombes RC: Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs 13(1), 1-13 (2002).
142. Plumb JA, Finn PW, Williams RJ et al.: Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol. Cancer Ther. 2(8), 721-728 (2003).
143. Magner WJ, Tomasi TB: Chromatin-immune connections: regulation of MHC and other genes. J. Reprod. Immunol. 48(1), 1-15 (2000).
144. Kim MS, Kwon HJ, Lee YM et al.: Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 7(4), 437-443 (2001).
145. Deroanne CF, Bonjean K, Servotte S et al.: Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene 21(3), 427-436 (2002).
146. Kwon HJ, Kim MS, Kim MJ, Nakajima H, Kim KW: Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int. J. Cancer 97(3), 290-296 (2002).
147. Liu LT, Chang HC, Chiang LC, Hung WC: Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res. 63(12), 3069-3072 (2003).
148. Xu WS, Perez G, Ngo L, Gui CY, Marks PA: Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res. 65(17), 7832-7839 (2005).
149. Kovacs JJ, Murphy PJ, Gaillard S et al.: HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18(5), 601-607 (2005).
150. Scuto A, Kirschbaum M, Kowolik C et al.: The novel histone deacetylase inhibitor, LBH589, induces expression of DNA damage response genes and apoptosis in Ph-acute lymphoblastic leukemia cells. Blood 111(10), 5093-5100 (2008).
151. Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM, Buggy JJ: HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc. Natl Acad. Sci. USA 104(49), 19482-19487 (2007).
152. Zhang Y, Carr T, Dimtchev A, Zaer N, Dritschilo A, Jung M: Attenuated DNA damage repair by trichostatin a through BRCA1 suppression. Radiat. Res. 168(1), 115-124 (2007).
153. Xue F, Michels KB: Intrauterine factors and risk of breast cancer: a systematic review and meta-ana lysis of current evidence. Lancet Oncol. 8(12), 1088-1100 (2007).
154. Yu X, Guo ZS, Marcu MG et al.: Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J. Natl Cancer Inst. 94(7), 504-513 (2002).
155. Fuino L, Bali P, Wittmann S et al.: Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol. Cancer Ther. 2(10), 971-984 (2003).
156. Sakaguchi H, Fujimoto J, Hong BL, Nakagawa Y, Tamaya T: Drastic decrease of progesterone receptor form B but not A mRNA refects poor patient prognosis in endometrial cancers. Gynecol. Oncol. 93(2), 394-399 (2004).
157. Karagiannis TC, El-Osta A: Clinical potential of histone deacetylase inhibitors as stand alone therapeutics and in combination with other chemotherapeutics or radiotherapy for cancer. Epigenetics 1(3), 121-126 (2006).
158. Glaser KB: HDAC inhibitors: clinical update and mechanism-based potential. Biochem. Pharmacol. 74(5), 659-671 (2007).
159. Dokmanovic M, Clarke C, Marks PA: Histone deacetylase inhibitors: overview and perspectives. Mol. Cancer Res. 5(10), 981-989 (2007). (Pubitemid 350080267)
160. Yang X, Ferguson AT, Nass SJ et al.: Transcriptional activation of estrogen receptor a in human breast cancer cells by histone deacetylase inhibition. Cancer Res. 60(24), 6890-6894 (2000).
161. Piekarz RL, Frye AR, Wright JJ et al.: Cardiac studies in patients treated with depsipeptide, FK228, in a Phase II trial for T-cell lymphoma. Clin. Cancer Res. 12(12), 3762-3773 (2006).
162. Garcia-Manero G, Yang H, Bueso-Ramos C et al.: Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 111(3), 1060-1066 (2008).
163. Giles F, Fischer T, Cortes J et al.: A Phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res. 12(15), 4628-4635 (2006).
164. Sharma S, Vogelzang NJ, Beck J et al.: Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of lbh589, a novel deacetylase (DAC) inhibitor given intravenously on a new once weekly schedule. J. Clin. Oncol. 25(18S), 14019 (2007).
165. Zhang L, Lebwohl D, Masson E, Laird G, Cooper MR, Prince HM: Clinically relevant qtc prolongation is not associated with current dose schedules of LBH589 (panobinostat). J. Clin. Oncol. 26(2), 332-333; discussion 333-334 (2008).
166. Brunetto AT, Ang JE, Lal R: A frst-in-human Phase I study of 4SC-201, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 27(Suppl. 15) (2009) (Abstract 3530).
167. Postel-Vinay S, Kristeleit R, Fong P et al.: Preliminary results of an open-label Phase I harmacokinetic/pharmacodynamic study of JNJ26481585: early evidence of antitumor activity. J. Clin. Oncol. 27(Suppl.) (2009) (Abstract E13504).
168. Zambrano P, Segura-Pacheco B, Perez-Cardenas E et al.: A Phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes. BMC Cancer 5, 44 (2005).
169. Marshall JL, Rizvi N, Kauh J et al.: A Phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Exp. Ther. Oncol. 2(6), 325-332 (2002).
170. Furumai R, Matsuyama A, Kobashi N et al.: FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62(17), 4916-4921 (2002).
171. Robey RW, Zhan Z, Piekarz RL, Kayastha GL, Fojo T, Bates SE: Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176). Clin. Cancer Res. 12(5), 1547-1555 (2006).
172. Saito A, Yamashita T, Mariko Y et al.: A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl Acad. Sci. USA 96(8), 4592-4597 (1999).
173. Siu LL, Pili R, Duran I et al.: Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J. Clin. Oncol. 26(12), 1940-1947 (2008).
174. Anglesio MS, Arnold JM, George J et al.: Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol. Cancer Res. 6(11), 1678-1690 (2008).
175. Staub J, Chien J, Pan Y et al.: Epigenetic silencing of HSULF-1 in ovarian cancer: implications in chemoresistance. Oncogene 26(34), 4969-4978 (2007).
176. Luczak MW, Jagodzinski PP: Apicidin down-regulates human papillomavirus type 16 E6 and E7 transcripts and proteins in SiHa cervical cancer cells. Cancer Lett. 272(1), 53-60 (2008).
177. Modesitt SC, Sill M, Hoffman JS, Bender DP: A Phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study. Gynecol. Oncol. 109(2), 182-186 (2008).
178. Vansteenkiste J, van Cutsem E, Dumez H et al.: Early Phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest. New Drugs 26(5), 483-488 (2008).
179. Luu TH, Morgan RJ, Leong L et al.: A Phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a california cancer consortium study. Clin. Cancer Res. 14(21), 7138-7142 (2008).
180. Finkler NJ, Dizon DS, Braly P et al.: Phase II multicenter trial of the histone deactylase inhibitor (HDACi) belinostat, carboplatin and paclitaxel (BelCaP) in patients (pts) with relapsed epithelial ovarian cancer (EOC). J. Clin. Oncol. 26(Suppl.) (2008) (Abstract 5519).
181. Miranda TB, Cortez CC, Yoo CB et al.: Dznep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol. Cancer Ther. 8(6), 1579-1588 (2009).
182. Fiskus W, Wang Y, Sreekumar A et al.: Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114(13), 2733-2743 (2009).
183. Garzon R, Liu S, Fabbri M et al.: MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3a and 3b and indirectly DNMT1. Blood 113(25), 6411-6418 (2009).
184. Mackay H, Hirte H W, Covens A: A Phase II trial of the histone
185. Conte P, Campone M, Pronzato P et al.: Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): preliminary safety and tolerability results. J. Clin. Oncol. 27(Suppl. 15) (2009) (Abstract 1081).
186. Gradishar WJ, Krasnojon D, Cheporov S et al.: Signifcantly longer progression-free survival with nab-paclitaxel compared with docetaxel as frst-line therapy for metastatic breast cancer. J. Clin. Oncol. 27(22), 3611-3619 (2009).
187. Widschwendter M, Apostolidou S, Jones A et al.: HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer. Int. J. Cancer 125(9), 2214-2218 (2009).
188. Apostolidou S, Hadwin R, Burnell M et al.: DNA methylation ana lysis in liquid based cytology for cervical cancer screening. Int. J. Cancer 125(12), 2995-3002 (2009).
189. Su HY, Lai HC, Lin YW, Chou YC, Liu CY, Yu MH: An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int. J. Cancer 124(2), 387-393 (2009).
190. Melnikov A, Scholtens D, Godwin A, Levenson V: Differential methylation profle of ovarian cancer in tissues and plasma. J. Mol. Diagn. 11(1), 60-65 (2009).
191. Dong SM, Kim HS, Rha SH, Sidransky D: Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clin. Cancer Res. 7(7), 1982-1986 (2001).
192. Shivapurkar N, Sherman ME, Stastny V et al.: Evaluation of candidate methylation markers to detect cervical neoplasia. Gynecol. Oncol. 107(3), 549-553 (2007).
193. Yang HJ, Liu VW, Wang Y et al.: Detection of hypermethylated genes in tumor and plasma of cervical cancer patients. Gynecol. Oncol. 93(2), 435-440 (2004). (Pubitemid 38507614)
194. Lai HC, Lin Y W, Huang TH et al.: Identifcation of novel DNA methylation markers in cervical cancer. Int. J. Cancer 123(1), 161-167 (2008).
195. Neyaz MK, Kumar RS, Hussain S et al.: Effect of aberrant promoter methylation of FHIT and RASSF1A genes on susceptibility to cervical cancer in a North Indian population. Biomarkers 13(6), 597-606 (2008).
196. Kahn SL, Ronnett BM, Gravitt PE, Gustafson KS: Quantitative methylation-specifc PCR for the detection of aberrant DNA methylation in liquid-based pap tests. Cancer 114(1), 57-64 (2008).
197. Sova P, Feng Q, Geiss G et al.: Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray ana lysis. Cancer Epidemiol. Biomarkers Prev. 15(1), 114-123 (2006).
198. Feng Q, Hawes SE, Stern JE et al.: Promoter hypermethylation of tumor suppressor genes in urine from patients with cervical neoplasia. Cancer Epidemiol. Biomarkers Prev. 16(6), 1178-1184 (2007).
199. Feng Q, Balasubramanian A, Hawes SE et al.: Detection of hypermethylated genes in women with and without cervical neoplasia. J. Natl Cancer Inst. 97(4), 273-282 (2005).
200. Hublarova P, Hrstka R, Rotterova P et al.: Prediction of human papillomavirus 16 E6 gene expression and cervical intraepithelial neoplasia progression by methylation status. Int. J. Gynecol. Cancer 19(3), 321-325 (2009).
201. Shukla S, Mirza S, Sharma G, Parshad R, Gupta SD, Ralhan R: Detection of RASSF1A and RARb hypermethylation in serum DNA from breast cancer patients. Epigenetics 1(2), 88-93 (2006).
202. Mirza S, Sharma G, Prasad CP et al.: Promoter hypermethylation of TMS1, BRCA1, ERa and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci. 81(4), 280-287 (2007).
203. ARF, CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life Sci. 80(20), 1873-1881 (2007). (Pubitemid 46562520)
204. Taback B, Giuliano AE, Lai R et al.: Epigenetic ana lysis of body fuids and tumor tissues: application of a comprehensive molecular assessment for early-stage breast cancer patients. Ann. NY Acad. Sci. 1075, 211-221 (2006).
205. Dulaimi E, Hillinck J, Ibanez De Caceres I, Al-Saleem T, Cairns P: Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin. Cancer Res. 10(18 Pt 1), 6189-6193 (2004). (Pubitemid 39287525)
206. Krassenstein R, Sauter E, Dulaimi E et al.: Detection of breast cancer in nipple aspirate fuid by CpG island hypermethylation. Clin. Cancer Res. 10(1 Pt 1), 28-32 (2004).
207. Fackler MJ, Rivers A, Teo WW et al.: Hypermethylated genes as biomarkers of cancer in women with pathologic nipple discharge. Clin. Cancer Res. 15(11), 3802-3811 (2009).
208. Lee JS, Fackler MJ, Teo WW et al.: Quantitative promoter hypermethylation profles of ductal carcinoma in situ in North American and Korean women: potential applications for diagnosis. Cancer Biol. Ther. 7(9), 1398-1406 (2008).
209. Jeronimo C, Monteiro P, Henrique R et al.: Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fne-needle aspirate washings of breast lesions. Breast Cancer Res. Treat. 109(1), 27-34 (2008).
210. Wei SH, Chen CM, Strathdee G et al.: Methylation microarray ana lysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifes candidate epigenetic markers. Clin. Cancer Res. 8(7), 2246-2252 (2002).
211. Wiley A, Katsaros D, Fracchioli S, Yu H: Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int. J. Gynecol. Cancer 16(1), 210-218 (2006).
212. Wiley A, Katsaros D, Chen H et al.: Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 107(2), 299-308 (2006).
213. Chan MW, Wei SH, Wen P et al.: Hypermethylation of 18s and 28s ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin. Cancer Res. 11(20), 7376-7383 (2005).
214. Fiegl H, Windbichler G, Mueller-Holzner E et al.: Hoxa11 DNA methylation-a novel prognostic biomarker in ovarian cancer. Int. J. Cancer 123(3), 725-729 (2008).
215. Muller HM, Millinger S, Fiegl H et al.: Analysis of methylated genes in peritoneal fuids of ovarian cancer patients: a new prognostic tool. Clin. Chem. 50(11), 2171-2173 (2004).
216. Pattamadilok J, Huapai N, Rattanatanyong P et al.: Line-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. Int. J. Gynecol. Cancer 18(4), 711-717 (2008).
217. Wong YF, Chung TK, Cheung TH et al.: Methylation of p16INK4A in primary gynecologic malignancy. Cancer Lett. 136(2), 231-235 (1999).
218. Ren CC, Miao XH, Yang B, Zhao L, Sun R, Song WQ: Methylation status of the fragile histidine triad and e-cadherin genes in plasma of cervical cancer patients. Int. J. Gynecol. Cancer 16(5), 1862-1867 (2006). (Pubitemid 44470047)
219. Narayan G, Arias-Pulido H, Koul S et al.: Frequent promoter methylation of CDH1, DAPK, RARB, and HIC1 genes in carcinoma of cervix uteri: its relationship to clinical outcome. Mol. Cancer 2, 24 (2003).
220. Cheung TH, Lo K W, Yim SF et al.: Epigenetic and genetic alternation of PTEN in cervical neoplasm. Gynecol. Oncol. 93(3), 621-627 (2004).
221. Kloth JN, Kenter GG, Spijker HS et al.: Expression of Smad2 and Smad4 in cervical cancer: absent nuclear Smad4 expression correlates with poor survival. Mod. Pathol. 21(7), 866-875 (2008).
222. Terra AP, Murta EF, Maluf PJ, Caballero OL, Brait M, Adad SJ: Aberrant promoter methylation can be useful as a marker of recurrent disease in patients with cervical intraepithelial neoplasia grade III. Tumori 93(6), 572-579 (2007).
223. Jo H, Kang S, Kim JW et al.: Hypermethylation of the COX-2 gene is a potential prognostic marker for cervical cancer. J. Obstet. Gynaecol. Res. 33(3), 236-241 (2007).
224. Widschwendter A, Muller HM, Hubalek MM et al.: Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. Gynecol. Oncol. 93(2), 407-416 (2004).
225. Muller HM, Widschwendter A, Fiegl H et al.: A DNA methylation pattern similar to normal tissue is associated with better prognosis in human cervical cancer. Cancer Lett. 209(2), 231-236 (2004).
226. Muller HM, Widschwendter A, Fiegl H et al.: DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res. 63(22), 7641-7645 (2003).
227. Elsheikh SE, Green AR, Rakha EA et al.: Global histone modifcations in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res. 69(9), 3802-3809 (2009).
228. Kioulafa M, Kaklamanis L, Stathopoulos E, Mavroudis D, Georgoulias V, Lianidou ES: Kallikrein 10 (klk10) methylation as a novel prognostic biomarker in early breast cancer. Ann. Oncol. 20(6), 1020-1025 (2009).
229. Kioulafa M, Balkouranidou I, Sotiropoulou G et al.: Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer. Int. J. Cancer 25(12), 2887-2892 (2009).
230. Kioulafa M, Kaklamanis L, Mavroudis D, Georgoulias V, Lianidou ES: Prognostic signifcance of RASSF1A promoter methylation in operable breast cancer. Clin. Biochem. 42(10-11), 970-975 (2009).
231. Hartmann O, Spyratos F, Harbeck N et al.: DNA methylation markers predict outcome in node-positive, estrogen receptor-positive breast cancer with adjuvant anthracycline-based chemotherapy. Clin. Cancer Res. 15(1), 315-323 (2009).
232. Jing F, Jun L, Yong Z et al.: Multigene methylation in serum of sporadic Chinese female breast cancer patients as a prognostic biomarker. Oncology 75(1-2), 60-66 (2008).
233. Veeck J, Geisler C, Noetzel E et al.: Epigenetic inactivation of the secreted frizzled-related protein-5 (SFRP5) gene in human breast cancer is associated with unfavorable prognosis. Carcinogenesis 29(5), 991-998 (2008).
234. Nimmrich I, Sieuwerts AM, Meijer-van Gelder ME et al.: DNA hypermethylation of pitx2 is a marker of poor prognosis in untreated lymph node-negative hormone receptor-positive breast cancer patients. Breast Cancer Res. Treat. 111(3), 429-437 (2008).
235. Maier S, Nimmrich I, Koenig T et al.: DNA-methylation of the homeodomain transcription factor pitx2 reliably predicts risk of distant disease recurrence in tamoxifen-treated, node-negative breast cancer patients-technical and clinical validation in a multi-centre setting in collaboration with the European Organisation for Research and Treatment of Cancer (EORTC) pathobiology group. Eur. J. Cancer 43(11), 1679-1686 (2007).
236. Noetzel E, Veeck J, Niederacher D et al.: Promoter methylation-associated loss of id4 expression is a marker of tumour recurrence in human breast cancer. BMC Cancer 8, 154 (2008).
237. Weiss AJ, Stambaugh JE, Mastrangelo MJ, Laucius JF, Bellet RE: Phase I study of 5-azacytidine (NSC-102816). Cancer Chemother. Rep. 56(3), 413-419 (1972).
238. Shnider BI, Baig M, Colsky J: A Phase I study of 5-azacytidine (NSC-102816). J. Clin. Pharmacol. 16(4), 205-212 (1976).
239. Aparicio A, Eads CA, Leong LA et al.: Phase I trial of continuous infusion 5-aza-2́-deoxycytidine. Cancer Chemother. Pharmacol. 51(3), 231-239 (2003).
240. Kelly WK, Richon VM, O'Connor O et al.: Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin. Cancer Res. 9(10 Pt 1), 3578-3588 (2003).
241. Kelly WK, O'Connor OA, Krug LM et al.: Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 23(17), 3923-3931 (2005).
242. Prince HM, George D, Patnaik A: Phase I study of oral LBH589, a novel deacetylase (DAC) inhibitor in advanced solid tumors and non-hodgkin's lymphoma. J. Clin. Oncol. 25(18S), 3500 (2007) (Meeting abstract).
243. Gore L, Rothenberg ML, O'Bryant CL et al.: A Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin. Cancer Res. 14(14), 4517-4525 (2008).
244. Ryan QC, Headlee D, Acharya M et al.: Phase I and pharmacokinetic study of ms-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 23(17), 3912-3922 (2005).
245. Kummar S, Gutierrez M, Gardner ER et al.: Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin. Cancer Res. 13(18 Pt 1), 5411-5417 (2007).
246. Hatada I, Kato A, Morita S et al.: A microarray-based method for detecting loci. J. Hum. Genet. 47(8), 448-451 (2002).
247. Uhlmann K, Brinckmann A, Toliat MR et al.: Evaluation of a potential epigenetic biomarker by quantitative methyl-single nucleotide polymorphism. Electrophoresis 23(24), 4072-4079 (2002).
248. Margulies M, Egholm M, Altman WE et al.: Genome sequencing in microfabricated high-density picolitre reactors. Nature 437(7057), 376-380 (2005)
249. Core LJ, Waterfall JJ, Lis JT: Nascent RNA sequencing reveals widespread pausing and divergent initiation at human promoters. Science 322(5909), 1845-1848 (2008).
250. Preker P, Nielsen J, Kammler S et al.: RNA exosome depletion reveals transcription upstream of active human promoters. Science 322(5909), 1851-1854 (2008).
251. Brodersen DE, Clemons WM Jr, Carter A P, Wimberly BT, Ramakrishnan V: Crystal structure of the 30 S ribosomal subunit from Thermus thermophilus: structure of the proteins and their interactions with 16 S RNA. J. Mol. Biol. 316(3), 725-768 (2002).
252. Verdel A, Vavasseur A, Le Gorrec M, Touat-Todeschini L: Common themes in siRNA-mediated epigenetic silencing pathways. Int. J. Dev. Biol. 53(2-3), 245-257 (2009).